Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2018 | Multiple myeloma musings: highlights from 2018 data

Joshua Richter • 16 Jan 2019
ASH 2018
Multiple Myeloma Antibodies CAR-T Daratumumab Dexamethasone Lenalidomide
LEGEND-2 MAIA

Joshua Richter, MD, of Mount Sinai Medical Center, New York, NY, gives us his take on the key highlights in multiple myeloma (MM) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Dr Richter discusses the up-and-coming new tools being investigated in clinical trials, and also reveals the use of old tools in novel ways, notably in the MAIA study (NCT02252172).

More from Joshua Richter

The use of CELMoDs to improve outcomes with T-cell redirection therapies in RRMM 1:43
The use of CELMoDs to improve outcomes with T-cell redirection therapies in RRMM
Joshua Richter • 19 Sep 2025
How does linvoseltamab compare with other bispecific antibodies in multiple myeloma? 1:34
How does linvoseltamab compare with other bispecific antibodies in multiple myeloma?
Joshua Richter • 19 Sep 2025
Optimizing reporting of infection rates in clinical trials of bispecific antibodies in myeloma 3:04
Optimizing reporting of infection rates in clinical trials of bispecific antibodies in myeloma
Joshua Richter • 4 Mar 2025
What lies ahead for bispecifics in multiple myeloma? 2:02
What lies ahead for bispecifics in multiple myeloma?
Joshua Richter • 4 Mar 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals